Is CRISPR Therapeutics Stock a Buy Now?
Over the past five years, CRISPR Therapeutics' (NASDAQ: CRSP) shares have significantly lagged broader equities. That's despite the company earning approval for its first commercialized medicine, Casgevy, in 2023. If this milestone did not help the biotech reverse course, is there still hope that CRISPR Therapeutics can turn things around? Let's find out whether it is worth buying the company's shares today.
Image source: Getty Images.
The biggest catalysts for smaller, clinical-stage biotechs tend to be clinical progress. By the time they launch their first medicines, long-term shareholders are already taking some profits. That partly explains why CRISPR Therapeutics' stock has been southbound, but there is more to the story. A strong commercial uptake for a new drug can also push a biotech's shares in the right direction. Unfortunately, Casgevy's progress so far hasn't exactly been impressive, even with help from Vertex Pharmaceuticals, with which CRISPR Therapeutics developed this therapy.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Klarer Community-Favorit: Vertex Pharmaceuticals Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Für Vertex Pharmaceuticals Inc. ergibt sich mit einem Kursziel von 475 € ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 469.3 €.
